4. Erleada

(Johnson & Johnson)

Active ingredient: apalutamide
Disease: non-metastatic prostate cancer
Peak sales estimate: $1.3 billion
Approved: Feb. 14, 2018
Company: Johnson & Johnson

The scoop: In February, J&J’s Erleada picked up the first FDA approval for non-metastatic, castration-resistant prostate cancer, while also being the first to do so using a new clinical trial endpoint of metastasis-free survival. In addition, it was greenlighted months before its decision date—giving it a big head start on market share compared to its main competitor, Pfizer and Astellas’ Xtandi (enzalutamide), which was approved for the same indication in July. Erleada also represents J&J’s follow-up to its Janssen unit’s blockbuster prostate cancer drug, Zytiga (abiraterone acetate), which raised $2.5 billion in sales last year but is now facing pressure from generics. In May 2017, J&J listed 11 pipeline candidates it believed could achieve blockbuster status by 2021, with Erleada being the second on the list to receive approval after the PARP inhibitor Zejula (niraparib). — Conor Hale

4. Erleada

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.